Almirall gets EC approval for psoriasis drug
20 September 2018 | News
Sun Pharma's out-licensed Ilumetri (tildrakizumab) has received approval from the European Commission.
Sun Pharma has said that Spanish firm Almirall has received approval from the European Commission (EC) for Ilumetri, a drug used for treating psoriasis.
In July 2016, Sun Pharma out-licensed Ilumetri (tildrakizumab) to Almirall, for the development and commercialisation of the product in Europe.
"As indicated by Almirall, rollout of Ilumetri in Europe will start in the next few weeks," Sun Pharma said in a statement.
Psoriasis is a chronic immune disease that appears on the skin. It affects an estimated 7.8 million adults in Europe and around 125 million people worldwide.
